SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant Delta)

COVID-19 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta); 2019-nCoV Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta); 2019-nCoV Spike Protein S1 (RBD) Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta)

Colorimetric

32160000

After reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Plate and reagents should reach room temperature before use.

Screening Assay. To measure the presence of neutralizing/blocking antibodies in human serum/plasma that inhibit the binding of the SARS-CoV-2 Spike (RBD) (B.1.617.2 Variant, Delta) protein to its human receptor ACE2. Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.The SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta) contains key reagents required to test the presence of functional neutralizing antibodies against SARS-CoV-2 (variant B.1.617.2) present in the serum or plasma or/and to test the cross-reaction of SARS-CoV-2 neutralizing antibodies directed to previous variants. It is an easy and fast alternative to the classical neutralization assay using Vero E6 cells. This Detection Kit is based on a colorimetric reaction, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 (variant Kappa) to its human receptor ACE2. The presence of neutralizing/blocking antibodies in the samples are detected by reduction of signal indicating the inhibition of the Spike-ACE2 binding. Recently, a new variant of SARS-CoV-2, called B.1.617 was detected in India. Three sublineages have been found, B.1.617.1 (variant Kappa) and B.1.617.3 containing 4 mutations in the Spike protein with a double mutations in the Receptor Binding Region (L452R, E484Q) and B.1.617.2 (variant Delta) that is different since it contains the mutation T478K instead of E484Q. The variant Delta (B.1.617.2) of the SARS-CoV-2 coronavirus has evolved as fast-growing variant outpacing other variants.

Box

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.The SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.2 Variant, Delta) contains key reagents required to test the presence of functional neutralizing antibodies against SARS-CoV-2 (variant B.1.617.2) present in the serum or plasma or/and to test the cross-reaction of SARS-CoV-2 neutralizing antibodies directed to previous variants. It is an easy and fast alternative to the classical neutralization assay using Vero E6 cells. This Detection Kit is based on a colorimetric reaction, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 (variant Kappa) to its human receptor ACE2. The presence of neutralizing/blocking antibodies in the samples are detected by reduction of signal indicating the inhibition of the Spike-ACE2 binding. Recently, a new variant of SARS-CoV-2, called B.1.617 was detected in India. Three sublineages have been found, B.1.617.1 (variant Kappa) and B.1.617.3 containing 4 mutations in the Spike protein with a double mutations in the Receptor Binding Region (L452R, E484Q) and B.1.617.2 (variant Delta) that is different since it contains the mutation T478K instead of E484Q. The variant Delta (B.1.617.2) of the SARS-CoV-2 coronavirus has evolved as fast-growing variant outpacing other variants.

Plasma, Serum

To measure the presence of neutralizing/blocking antibodies in human serum/plasma that inhibit the binding of the SARS-CoV-2 Spike (RBD) (B.1.617.2 Variant, Delta) protein to its human receptor ACE2.

Non-hazardous

General Purpose Cell Biology Kits

41116111

12 months after the day of manufacturing. See expiry date on ELISA Kit box.